Cizzle Bio Highlights CIZ1B Biomarker at Next Generation DX Summit 2026
Dr. Lary Robinson of Moffitt Cancer Center presents at the Next Generation DX Summit 2026 in Washington, DC.
Cizzle Bio attended the 18th Annual Next Generation DX Summit, held August 24–26, 2026 in Washington, DC, where leaders across molecular diagnostics, precision medicine, oncology, biotechnology, and clinical laboratory innovation gathered to discuss the future of earlier disease detection.
The meeting also provided a timely setting for Cizzle Bio to highlight new clinical and scientific discussion around CIZ1B, the company’s biomarker blood test for lung cancer. In a PRNewswire announcement, Cizzle Bio announced its participation in the summit and highlighted Dr. Lary Robinson’s presentation on the potential role of CIZ1B in lung cancer detection and patient management.
CIZ1B Biomarker Blood Test featured in early cancer surveillance discussion
A key highlight of the meeting was a featured presentation by Dr. Lary A. Robinson, director of the Lung Cancer Early Detection (LEAD) Center at Moffitt Cancer Center, titled “Potential of the CIZ1B Biomarker to Redefine Early Lung Cancer Detection.”
Presented as part of the Early Cancer Surveillance track, the session examined the potential role of CIZ1B in lung cancer detection and patient management, including an overview of the clinical study underway at Moffitt Cancer Center. The discussion underscored the growing importance of molecular diagnostics and blood-based biomarker testing as clinicians and researchers continue to explore better tools for identifying cancer-related signals earlier in the diagnostic pathway.
Dr. Robinson discusses lung cancer detection and the clinical potential of blood-based biomarkers during the Early Cancer Surveillance track.
Key takeaways from Dr. Robinson’s presentation
Dr. Robinson’s presentation focused on several practical challenges in early lung cancer detection and where blood-based biomarkers may provide additional clinical information:
Low-dose CT screening remains underused. LDCT is an important tool for lung cancer screening, but limited participation means many eligible patients may not be screened.
Indeterminate pulmonary nodules create clinical uncertainty. Approximately 1.6 million lung nodules are identified annually in the United States, creating a need for tools that may help clinicians determine which nodules warrant further evaluation.
Blood-based biomarkers may help support nodule assessment. As Dr. Robinson noted in Cizzle Bio’s announcement, “A reliable blood test could help assess indeterminate lung nodules and reduce unnecessary invasive procedures.”
Biomarkers may also have a role after treatment. Dr. Robinson also noted the potential for blood-based biomarkers to provide additional information for monitoring patients following treatment.
The Moffitt clinical study is evaluating CIZ1B in real clinical scenarios. The study is assessing CIZ1B’s potential to distinguish malignant from benign nodules, stratify recurrence risk after curative treatment, and support surveillance for recurrence or second primary lung cancers.
Scientific foundation for CIZ1B
CIZ1B is a blood-based biomarker associated with early-stage lung cancer and developed from 30 years of research at the University of York. A recently published peer-reviewed study in The Journal of Applied Laboratory Medicine evaluating the scalable ELISA assay reported sensitivity of approximately 94% and a negative predictive value of 97%.
Connecting scientific interest with clinical access
For Cizzle Bio, the summit came at an important moment. The CIZ1B Biomarker Blood Test for Lung Cancer is now commercially available to licensed healthcare providers in the Dallas-Fort Worth and San Antonio metropolitan areas.
That means the CIZ1B biomarker is not only part of an ongoing scientific conversation. It is also part of an emerging clinical access pathway for providers who want additional biomarker-based information to support lung cancer assessment.
The CIZ1B test is designed to complement, not replace, clinical judgment, imaging, LDCT screening where appropriate, and other diagnostic information. For providers, the near-term opportunity is to understand where CIZ1B may fit within broader lung cancer evaluation workflows and how to get set up to order the test.
Providers who want additional context can also review the CIZ1B Biomarker Blood Test Provider FAQ, which covers ordering setup, clinical use cases, LDCT, result interpretation, clinical evidence, and clinician resources.
Why the conversation matters
Lung cancer remains one of the most serious cancer challenges because it is often identified after symptoms appear or disease has progressed. Earlier detection strategies continue to be a major area of clinical and research focus.
Biomarker testing may help expand the information available to clinicians as they evaluate patients, particularly when combined with established tools and guideline-informed care pathways. Discussions like those at the Next Generation DX Summit are important because they bring together the scientific, clinical, laboratory, and commercialization perspectives needed to move promising diagnostic technologies toward real-world use.
Next step for licensed providers
Licensed healthcare providers in Dallas-Fort Worth and San Antonio can review CIZ1B ordering setup stepsthrough Cizzle Bio’s clinician resources.
Related resource: CIZ1B Biomarker Blood Test Provider FAQ
